Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 63,61 € ( 1,78 %). Der Median liegt bei 63,61 € ( 1,78 %).
Kaufen |
4 |
Halten |
2
|
Verkaufen |
0 |
Scoring-Modelle
Dividenden-Strategie | 0 / 15 |
HGI-Strategie | 9 / 18 |
Levermann-Strategie | 0 / 13 |
Beliebteste Broker
News
- 18.09. - 22:59 Uhr
Axonics Prevails in Patent Infringement Lawsuit with Medtronic
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that the jury has returned a unanimous verdict in the patent infringement lawsuit brought by Medtronic against Axonics in U.S. District Court for the Central District of California. The jury found that Axonics does not infringe any of the three patents-in-suit. “A jury of our peers recognized that Axonics' proprietary tined lead design and temperature sensor technology is differentiated from our competitor's intellect. » Mehr auf businesswire.com
- 01.08. - 22:26 Uhr
Axonics Modulation Technologies (AXNX) Surpasses Q2 Earnings and Revenue Estimates
Axonics Modulation Technologies (AXNX) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to loss of $0.15 per share a year ago. » Mehr auf zacks.com
- 20.05. - 09:01 Uhr
Axonics, Inc. (NASDAQ:AXNX) Shares Sold by Amalgamated Bank
Amalgamated Bank cut its holdings in shares of Axonics, Inc. (NASDAQ:AXNX – Free Report) by 6.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,052 shares of the company’s stock after selling 499 shares during the period. Amalgamated Bank’s holdings in Axonics were worth $439,000 at the end of the most recent quarter. Several other institutional investors and hedge funds have also added to or reduced their stakes in AXNX. Headlands Technologies LLC acquired a new stake in shares of Axonics during the fourth quarter valued at approximately $53,000. RiverPark Advisors LLC acquired a new stake in shares of Axonics during the third quarter valued at approximately $58,000. C M Bidwell & Associates Ltd. raised its holdings in shares of Axonics by 108.2% during the third quarter. C M Bidwell & Associates Ltd. now owns 1,270 shares of the company’s stock valued at $71,000 after acquiring an additional 660 shares during the period. Sentry Investment Management LLC acquired a new stake in shares of Axonics during the fourth quarter valued at approximately $125,000. Finally, Covestor Ltd raised its holdings in shares of Axonics by 40.8% during the third quarter. Covestor Ltd now owns 3,143 shares of the company’s stock valued at $176,000 after acquiring an additional 911 shares during the period. 99.48% of the stock is owned by institutional investors and hedge funds. Axonics Stock Down 0.2 % AXNX stock opened at $67.55 on Monday. The company has a market capitalization of $3.45 billion, a price-to-earnings ratio of -211.09 and a beta of 0.60. Axonics, Inc. has a 12 month low of $47.59 and a 12 month high of $69.68. The firm has a 50 day moving average of $67.72 and a two-hundred day moving average of $64.46. Axonics (NASDAQ:AXNX – Get Free Report) last posted its earnings results on Tuesday, April 30th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.32). The business had revenue of $91.41 million during the quarter, compared to the consensus estimate of $89.79 million. Axonics had a negative return on equity of 2.58% and a negative net margin of 4.12%. The business’s revenue was up 29.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.19) earnings per share. On average, research analysts expect that Axonics, Inc. will post 0.13 EPS for the current fiscal year. Wall Street Analysts Forecast Growth AXNX has been the topic of a number of recent analyst reports. Needham & Company LLC restated a “hold” rating on shares of Axonics in a report on Monday, May 6th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $71.00 price objective on shares of Axonics in a research note on Thursday, February 29th. Eight analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $70.73. Read Our Latest Analysis on Axonics Axonics Profile (Free Report) Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. » Mehr auf defenseworld.net
Unternehmenszahlen
(EUR) | Juni 2024 | |
---|---|---|
Umsatz | 106,72 Mio | 413,13% |
Bruttoeinkommen | 80,95 Mio | - |
Nettoeinkommen | 6,43 Mio | 195,55% |
EBITDA | 9,07 Mio | 55,63% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 3,15 Mrd € |
Anzahl Aktien | 51,12 Mio |
52 Wochen-Hoch/Tief | 62,43 € - 43,27 € |
Dividenden | Nein |
Beta | 0,82 |
KGV (PE Ratio) | 2.057,62 |
KGWV (PEG Ratio) | 22,70 |
KBV (PB Ratio) | 5,47 |
KUV (PS Ratio) | 8,59 |
Unternehmensprofil
Axonics, Inc. ist ein Medizintechnikunternehmen, das sich mit der Entwicklung und Vermarktung von sakralen Neuromodulationssystemen (SNM) befasst. Die SNM-Systeme des Unternehmens werden zur Behandlung von Patienten mit überaktiver Blase, einschließlich Harndranginkontinenz und Harndranghäufigkeit, sowie Stuhlinkontinenz und nicht-obstruktiver Harnverhaltung eingesetzt. Das firmeneigene wiederaufladbare SNM-System (r-SNM) gibt milde elektrische Impulse an den anvisierten Sakralnerv ab, um die normale Kommunikation zum und vom Gehirn wiederherzustellen und die Symptome von Blasen- und Darmfunktionsstörungen zu lindern. Das Unternehmen bietet auch Bulkamid an, ein Mittel zur Ausdehnung der Harnröhre zur Behandlung der Stressharninkontinenz bei Frauen. Es vertreibt seine Produkte über einen Direktvertrieb und Händler in den Vereinigten Staaten, Großbritannien, Deutschland, den Niederlanden, den nordischen Ländern und international. Das Unternehmen war früher als Axonics Modulation Technologies, Inc. bekannt und änderte im März 2021 seinen Namen in Axonics, Inc. Axonics, Inc. wurde im Jahr 2012 gegründet und hat seinen Sitz in Irvine, Kalifornien.
Name | Axonics Modulation Technologies |
CEO | Raymond W. Cohen |
Sitz | Irvine,
ca USA |
Website | |
Industrie | Gesundheitstechnologie |
Börsengang | 31.10.2018 |
Mitarbeiter | 797 |
Ticker Symbole
Börse | Symbol |
---|---|
NASDAQ | AXNX |
Frankfurt | 0I3.F |
Düsseldorf | 0I3.DU |
München | 0I3.MU |
Assets entdecken
Shareholder von Axonics Modulation Technologies investieren auch in folgende Assets